Ibogaine Science and Research

There is more research on ibogaine than most people expect: over five hundred papers. What ibogaine is covers the compound itself, its history and its legal position; this page is about what the research does and does not establish. The difficulty is that almost none of it was done in a person, and the gap between those two literatures is where most confident claims come from.

The concentration problem, which decides almost everything

Ibogaine binds a great many things. The 1995 screen that established this tested more than fifty targets and found interactions with opioid, serotonin, muscarinic, dopamine-transport and NMDA sites. How ibogaine works takes each proposed mechanism in turn.

The load-bearing detail is the range at which it did so: one to a hundred micromolar.

Measured human blood concentrations after ordinary treatment doses sit far lower. In the Dutch hospital series the median peak was about 4.8 micromolar, with the upper quarter of patients above 6.1. The upper reaches of that hundred-micromolar range are simply not attained by a person who has taken this drug.

What the neuroplasticity claim actually rests on

The idea that ibogaine produces lasting change by promoting growth factors is the most widely repeated mechanistic claim about it. Its origin is a single 2005 paper in rats and human neuroblastoma cells, which showed that ibogaine raised GDNF in the midbrain, that injecting GDNF into the same region reproduced the effect on alcohol self-administration, and that blocking GDNF reduced it.

That is a strong piece of work. Three things about it are usually left out.

The follow-up that explains the durability, the self-sustaining loop in which GDNF drives more GDNF, was done entirely in cell culture.

The most careful replication in rats found the GDNF protein increase in one region only, the ventral tegmental area, and only at the higher of two doses. And on BDNF, the growth factor most often named in popular accounts, the same paper states that transcripts rose in several regions while no significant increase in BDNF protein was found in any of the areas studied.

And the laboratory that started this line drew its own conclusion: it went on to develop GDNF as the target and left ibogaine behind. Others took a different route and built analogues of the molecule itself, designed to keep the effect and drop the cardiac risk.

One more finding belongs here, because it contradicts the most common short description of what ibogaine does. In rats given ibogaine or noribogaine intravenously, neither drug altered extracellular dopamine in the nucleus accumbens. Whatever “resetting the reward system” means, that measurement does not support it.

What the animal literature honestly shows

A systematic review and meta-analysis of 27 animal studies is the most rigorous synthesis available, and it declares no conflicts of interest.

It found that ibogaine reduced drug self-administration, particularly in the first 24 hours; that it had no effect on conditioned place preference; that it caused motor impairment in that same first day; and that cerebral cell loss was observed even weeks after administration.

The twenty-four-hour window is the detail that most often disappears when this literature is summarised.

The pharmacology that is solid

The cardiac mechanism is the exception to everything above, and it is worth being clear that this is not a weakness of the field but a strength.

Ibogaine blocks the hERG potassium channel at low micromolar concentrations, replicated in independent laboratories, with a worked-out mechanism: it acts from inside the cell, only on channels that are open or inactivated, which is why the risk depends on heart rate and rhythm. The authors point out that several drugs have been withdrawn from the market for having hERG potency in the range of their therapeutic plasma concentrations.

Noribogaine, the metabolite, blocks it slightly harder and lasts far longer.

That is the best-established pharmacology on this page, and it concerns the harm rather than the benefit. Ibogaine and the heart carries the clinical side of it.

The single most informative human study

Fourteen patients in a Dutch hospital were given a treatment dose, genotyped, and had their blood sampled for a day while their symptoms and their ECGs were recorded. It is independent, declares no conflicts, and it tested the relationships everyone assumes.

What it found:

• Ibogaine concentration tracked QT prolongation. The harm has a dose-response.
• Ibogaine concentration also tracked the loss of coordination, strongly, at a rank correlation of 0.67.
• Noribogaine tracked neither, which is why the authors conclude both effects are driven mainly by the parent compound.
• Neither compound tracked the severity of withdrawal.

The parent drug predicted both harms. Nothing predicted the benefit.

What has never been measured in a human

This list is the honest state of the field, and every line of it is an absence rather than a negative result.

1. Any neurotrophin, after ibogaine, in anyone.
2. Brain concentration of ibogaine or noribogaine.
3. Receptor occupancy at any proposed target.
4. Any dose-response study in patients. The 8 to 14 mg/kg range in clinical use comes from case series, not from dose finding.
5. Any comparison against standard opioid treatment.
6. Any prospective cohort large enough to estimate a death rate.
7. Any published randomised controlled trial reporting drug-use outcomes.

That last one has a page of its own: what the trials found sets out the nine registered studies, the two randomised trials that completed in 2024, and the fact that neither has reported.

The question underneath all of it, whether the treatment works and how often, has one too. Why there is no success rate traces the figures clinics quote back to the studies they came from.

How to read a mechanistic claim about ibogaine

Four questions handle most of what circulates.

1. What species? If the answer is rat, the claim is about rats.
2. At what concentration? Human peaks cluster around five micromolar and reach a little above six. Much beyond that, it is not happening in a person’s blood.
3. Transcript or protein? More messenger RNA is not more protein, and on BDNF the difference is the whole claim.
4. Who is disclosing what? A large part of the noribogaine mechanistic literature was produced in-house by a company developing it, disclosed each time. That does not make it wrong. It makes independent replication the thing to look for, and mostly it is not there.